en 38164428 <p>Background: The purpose of the study was to assess whether the coadministration of 150 <em>IU</em> of recombinant LH instead of 75 <em>IU</em> in women aged 35-39 improves the results in agonist ICSI cycles stimulated with 300 <em>IU</em> of recombinant FSH.<br /> Methods: In this study, two ovarian stimulation protocols coexisted which were identical except in the administered dose of recombinant LH, for which some patients received 150 <em>IU</em> (n=231) and some received 75 <em>IU</em> (n=216). Both groups received 300 <em>IU</em> of recombinant FSH. There were no differences in the demographic characteristics of both groups. Gonadotropins were reimbursed by the National Health System. Statistical analysis was performed by Student&rsquo;s t test, &chi;2, and ANCOVA. Significance level was established at p=0.05.<br /> Results: The number of retrieved oocytes was slightly higher in the 300/150 group (9.06&plusmn;5.53 vs. 8.61&plusmn;5.11), but the differences were not significant. Results were similar with the number of metaphase II oocytes (7.18&plusmn;4.86 vs. 6.72&plusmn;4.72) and the number of fertilized oocytes (4.64&plusmn;3.2 <em>vs.</em> 4.23&plusmn;2.72). The per-transfer clinical pregnancy rates exhibited close similarity between both groups (32.84% vs. 32.46%), as did the per-transfer live birth rates (29.90% vs. 30.37%) and the implantation rate. The rate of hyperstimulation syndrome (OHSS) as well as the rate of cancellation due to OHHS risk was similar in both groups. There was also no difference in the miscarriage rate. When results were expressed by per started cycle or by oocyte pick- up, the results remained very similar in both groups.<br /> Conclusion: In women aged 35-39 undergoing ovarian stimulation with recombinant FSH in agonist cycles, the coadministration of 75 or 150 UI of recombinant LH did not influence pregnancy rates. However, a slight increase in the number of retrieved oocytes should not be disregarded.</p> Agonist ICSI cycles, Coadministration, Luteinizing hormone, Oocyte, Ovarian stimulation, Pregnancy rate 269 279 https://www.jri.ir/article/140206 https://www.jri.ir/documents/fullpaper/en/140206.pdf RobertoMatorrasInstituto Valenciano de Infertilidad (IVI) Bilbao, Leioa, Spain11806FerminAspichuetaHuman Reproduction Unit, Cruces University Hospital, Barakaldo, Spain122617BegoñaPrietoInstituto Valenciano de Infertilidad (IVI) Bilbao, Leioa, Spain122618RosarioMendozaHuman Reproduction Unit, Cruces University Hospital, Barakaldo, Spain11798IkerMalainaDepartment of Mathematics, Faculty of Science and Technology, University of the Basque Country, Bizkaia, Spain122619BlancaCorralHuman Reproduction Unit, Cruces University Hospital, Barakaldo, Spain122620LorenaCrisolHuman Reproduction Unit, Cruces University Hospital, Barakaldo, Spain122621AlbertoVendrellBiocruces Bizkaia Health Research Institute, Barakaldo, Spainalberto.venber@gmail.com122622AntoniaExpositoHuman Reproduction Unit, Cruces University Hospital, Barakaldo, Spain122623